{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+vaccine&page=4", "query": { "intervention": "Peptide vaccine", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 749, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+vaccine&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+vaccine&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T02:31:10.515Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03251924", "title": "A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Tumors", "Neoplasm", "Malignancy" ], "interventions": [ { "name": "BMS-986226", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Tetanus Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2017-09-01", "completion_date": "2021-12-20", "has_results": true, "last_update_posted_date": "2023-02-28", "last_synced_at": "2026-10-12T02:31:10.515Z", "location_count": 5, "location_summary": "Boston, Massachusetts • St Louis, Missouri • Hackensack, New Jersey + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03251924" }, { "nct_id": "NCT04860297", "title": "A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "SARS-CoV-2" ], "interventions": [ { "name": "mRNA-1273", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 234, "start_date": "2021-04-16", "completion_date": "2023-05-22", "has_results": true, "last_update_posted_date": "2024-06-18", "last_synced_at": "2026-10-12T02:31:10.515Z", "location_count": 15, "location_summary": "Mesa, Arizona • San Diego, California • New Haven, Connecticut + 12 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04860297" }, { "nct_id": "NCT01008527", "title": "Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "CP 870,893", "type": "DRUG" }, { "name": "Peptides", "type": "BIOLOGICAL" }, { "name": "Oncovir poly IC:LC", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2009-10", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2015-09-24", "last_synced_at": "2026-10-12T02:31:10.515Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01008527" }, { "nct_id": "NCT03721679", "title": "Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Cancer" ], "interventions": [ { "name": "Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Oncovir, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2018-09-25", "completion_date": "2021-01-26", "has_results": false, "last_update_posted_date": "2021-02-01", "last_synced_at": "2026-10-12T02:31:10.515Z", "location_count": 3, "location_summary": "Chevy Chase, Maryland • Easton, Maryland • New York, New York", "locations": [ { "city": "Chevy Chase", "state": "Maryland" }, { "city": "Easton", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03721679" }, { "nct_id": "NCT00874861", "title": "HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Astrocytoma", "Oligoastrocytoma", "Oligodendroglioma" ], "interventions": [ { "name": "Peptide vaccine + Poly-ICLC", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Ian F. Pollack, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2009-04", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2015-12-08", "last_synced_at": "2026-10-12T02:31:10.515Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00874861" }, { "nct_id": "NCT00490529", "title": "Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Mantle-Cell" ], "interventions": [ { "name": "CpG-MCL vaccine", "type": "BIOLOGICAL" }, { "name": "PF-3512676", "type": "BIOLOGICAL" }, { "name": "Vaccine-primed T-cells", "type": "PROCEDURE" }, { "name": "Autologous hematopoietic stem cell transplant (HSCT)", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Standard induction chemotherapy", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Ronald Levy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 59, "start_date": "2009-08", "completion_date": "2017-12-14", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-10-12T02:31:10.515Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00490529" }, { "nct_id": "NCT02722512", "title": "Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Astrocytoma, Grade III", "Anaplastic Ependymoma", "Clear Cell Ependymoma", "Ependymoma" ], "interventions": [ { "name": "Heat Shock Protein Peptide Complex-96 (HSPPC-96)", "type": "BIOLOGICAL" }, { "name": "Tumor Resection", "type": "PROCEDURE" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 10, "start_date": "2016-07", "completion_date": "2019-11-13", "has_results": false, "last_update_posted_date": "2025-02-18", "last_synced_at": "2026-10-12T02:31:10.515Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02722512" }, { "nct_id": "NCT06514898", "title": "Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Group 3 Medulloblastoma", "Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma" ], "interventions": [ { "name": "TTRNA-DC vaccines with GM-CSF", "type": "BIOLOGICAL" }, { "name": "TTRNA-xALT", "type": "BIOLOGICAL" }, { "name": "Td vaccine", "type": "DRUG" }, { "name": "autologous HSCs", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "4 Years to 30 Years" }, "enrollment_count": 12, "start_date": "2025-05-05", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-12T02:31:10.515Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Gainesville, Florida", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06514898" }, { "nct_id": "NCT04024878", "title": "NeoVax With Nivolumab in Patients With Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "NeoVax", "type": "BIOLOGICAL" }, { "name": "Core Needle Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 22, "start_date": "2020-11-20", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-12T02:31:10.515Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04024878" }, { "nct_id": "NCT00458536", "title": "Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Renal Cancer" ], "interventions": [ { "name": "Dendritic Cell Tumor Fusion Vaccine", "type": "BIOLOGICAL" }, { "name": "Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2004-10", "completion_date": "2023-07", "has_results": true, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-12T02:31:10.515Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00458536" } ] }